2024
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study
Schmit N, Topazian H, Natama H, Bellamy D, Traoré O, Somé M, Rouamba T, Tahita M, Bonko M, Sourabié A, Sorgho H, Stockdale L, Provstgaard-Morys S, Aboagye J, Woods D, Rapi K, Datoo M, Lopez F, Charles G, McCain K, Ouedraogo J, Hamaluba M, Olotu A, Dicko A, Tinto H, Hill A, Ewer K, Ghani A, Winskill P. The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study. The Lancet Infectious Diseases 2024, 24: 465-475. PMID: 38342107, DOI: 10.1016/s1473-3099(23)00816-2.Peer-Reviewed Original ResearchDisability-adjusted life yearsClinical malariaMalaria vaccineClinical casesVaccine introductionVaccinated childrenVaccine efficacyYears of follow-upPhase 2b trialPhase 3 trialSub-Saharan AfricaSurrogate of protectionIncremental costAntibody titresPublic health impactSerum Institute of IndiaBill &Cost-effectiveness ratioChildren aged 2Dose pricesMalaria deathsMelinda Gates FoundationNIHR Oxford Biomedical Research CentreFollow-upUK Medical Research Council
2001
Preliminary study of cutaneous leishmaniasis in the town of Ouagadougou from 1996 to 1998.
Traoré K, Sawadogo N, Traoré A, Ouedraogo J, Traoré K, Guiguemdé T. Preliminary study of cutaneous leishmaniasis in the town of Ouagadougou from 1996 to 1998. Bulletin De La Société De Pathologie Exotique 2001, 94: 52-5. PMID: 11346985.Peer-Reviewed Original ResearchConceptsCutaneous leishmaniasisClinical formsHealth centersMonths of progressionAge of patientsFrequent clinical formPublic Health CenterDifferent clinical formsSite of infectionHealth care staffReports of casesProtocol therapyProspective studyRetrospective studyMean ageLocal etiologyInferior limbHigh incidenceCommon locationPatientsCare staffClinical casesCase managementDecisional algorithmLeishmaniasis